TGFB1 and neoplasm: Our multipronged approach addressed TGF-β1 inhibition in OS TME and reduced OS proliferation and metastasis via tumor-intrinsic (decreased proto-oncogene) and extrinsic immune-related factors (suppressed immune-suppressive TME) to achieve optimal conditions for enhanced immune-effector function and maximal clinical response in OS.